Trial Outcomes & Findings for A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors (NCT NCT01708161)
NCT ID: NCT01708161
Last Updated: 2018-09-13
Results Overview
Phase lb only
Recruitment status
TERMINATED
Study phase
PHASE1/PHASE2
Target enrollment
47 participants
Primary outcome timeframe
28 days
Results posted on
2018-09-13
Participant Flow
Patients with selected advanced solid tumors who had relapsed or progressed on standard therapy were treated in BYL719X2105J study with a combination of alpelisib and ganitumab. Phase I of the trial was by dose combination of the treatment. Phase II was by patients.
Participant milestones
| Measure |
BYL 200mg + AMG 12mg/kg
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 300mg + AMG 12mg/kg
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 350mg + AMG 12mg/kg
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
HR+BC - Phase II
Patients with PIK3CA mutated or amplified hormone receptor (HR) positive breast carcinoma (BC) were treated with alpelisib 300 mg once daily and ganitumab 12 mg/kg.
|
Ovarian - Phase II
Patients with PIK3CA mutated or amplified ovarian cancer were treated with alpelisib 300 mg once daily and ganitumab 12 mg/kg
|
Non-HR+BC/Ovarian - Phase II
Patients with other than Breast and Ovarian cancer treated in the phase II part
|
|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
4
|
10
|
10
|
16
|
6
|
1
|
|
Overall Study
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
4
|
10
|
10
|
16
|
6
|
1
|
Reasons for withdrawal
| Measure |
BYL 200mg + AMG 12mg/kg
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 300mg + AMG 12mg/kg
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 350mg + AMG 12mg/kg
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
HR+BC - Phase II
Patients with PIK3CA mutated or amplified hormone receptor (HR) positive breast carcinoma (BC) were treated with alpelisib 300 mg once daily and ganitumab 12 mg/kg.
|
Ovarian - Phase II
Patients with PIK3CA mutated or amplified ovarian cancer were treated with alpelisib 300 mg once daily and ganitumab 12 mg/kg
|
Non-HR+BC/Ovarian - Phase II
Patients with other than Breast and Ovarian cancer treated in the phase II part
|
|---|---|---|---|---|---|---|
|
Overall Study
Adverse Event
|
1
|
3
|
4
|
2
|
3
|
0
|
|
Overall Study
Death
|
0
|
0
|
0
|
1
|
0
|
1
|
|
Overall Study
Withdrawal by Subject
|
0
|
1
|
1
|
0
|
0
|
0
|
|
Overall Study
Administrative problems
|
0
|
1
|
0
|
0
|
0
|
0
|
|
Overall Study
Disease progression
|
3
|
5
|
5
|
13
|
3
|
0
|
Baseline Characteristics
Full analysis set
Baseline characteristics by cohort
| Measure |
BYL 200mg + AMG 12mg/kg
n=4 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 300mg + AMG 12mg/kg
n=10 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 350mg + AMG 12mg/kg
n=10 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
HR+BC - Phase II
n=16 Participants
Patients with PIK3CA mutated or amplified hormone receptor (HR) positive breast carcinoma (BC) were treated with alpelisib 300 mg once daily and ganitumab 12 mg/kg.
|
Ovarian - Phase II
n=6 Participants
Patients with PIK3CA mutated or amplified ovarian cancer were treated with alpelisib 300 mg once daily and ganitumab 12 mg/kg
|
Non-HR+BC/Ovarian - Phase II
n=1 Participants
Patients with other than Breast and Ovarian cancer treated in the phase II part
|
Total
n=47 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
50.5 years
STANDARD_DEVIATION 3.11 • n=5 Participants • Full analysis set
|
57.5 years
STANDARD_DEVIATION 15.55 • n=7 Participants • Full analysis set
|
63.7 years
STANDARD_DEVIATION 7.83 • n=5 Participants • Full analysis set
|
51.3 years
STANDARD_DEVIATION 8.04 • n=4 Participants • Full analysis set
|
59.7 years
STANDARD_DEVIATION 6.53 • n=21 Participants • Full analysis set
|
56.0 years
STANDARD_DEVIATION 0 • n=8 Participants • Full analysis set
|
56.3 years
STANDARD_DEVIATION 10.54 • n=8 Participants • Full analysis set
|
|
Sex: Female, Male
Female
|
4 Participants
n=5 Participants • Full analysis set
|
7 Participants
n=7 Participants • Full analysis set
|
7 Participants
n=5 Participants • Full analysis set
|
15 Participants
n=4 Participants • Full analysis set
|
6 Participants
n=21 Participants • Full analysis set
|
1 Participants
n=8 Participants • Full analysis set
|
40 Participants
n=8 Participants • Full analysis set
|
|
Sex: Female, Male
Male
|
0 Participants
n=5 Participants • Full analysis set
|
3 Participants
n=7 Participants • Full analysis set
|
3 Participants
n=5 Participants • Full analysis set
|
1 Participants
n=4 Participants • Full analysis set
|
0 Participants
n=21 Participants • Full analysis set
|
0 Participants
n=8 Participants • Full analysis set
|
7 Participants
n=8 Participants • Full analysis set
|
|
Race/Ethnicity, Customized
Caucasian
|
2 Participants
n=5 Participants
|
8 Participants
n=7 Participants
|
10 Participants
n=5 Participants
|
14 Participants
n=4 Participants
|
5 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
40 Participants
n=8 Participants
|
|
Race/Ethnicity, Customized
Asian
|
2 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
6 Participants
n=8 Participants
|
|
Race/Ethnicity, Customized
Native American
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
PRIMARY outcome
Timeframe: 28 daysPopulation: Dose determining set (DDS): DDS includes all patients from the safety set who either met the minimum treatment exposure and safety evaluation requirements without experiencing DLT within Cycle 1 or experienced a DLT at any time during Cycle 1.
Phase lb only
Outcome measures
| Measure |
BYL 200mg + AMG 12mg/kg
n=3 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 300mg + AMG 12mg/kg
n=8 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 350mg + AMG 12mg/kg
n=9 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
|---|---|---|---|
|
Dose Limiting Toxicities (DLTs) - Phase Ib
Drug hypersensitivity
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Dose Limiting Toxicities (DLTs) - Phase Ib
Hyperglycemia
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Dose Limiting Toxicities (DLTs) - Phase Ib
Rash maculopapular
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Dose Limiting Toxicities (DLTs) - Phase Ib
Urticaria
|
0 Participants
|
1 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Approximately 1 year (since initiation of Phase II, Dec 2013, till Primary CSR cut off 06Jan2015)Population: Full analysis set (FAS). The full analysis set (FAS) includes all patients who received at least one full or partial dose of alpelisib or ganitumab. Patients were analyzed according to the planned treatment combination.
The antitumor activity of alpelisib in combination with ganitumab in patients with PIK3CA mutated or amplified hormone receptor positive (HR+) breast (arm 1) or ovarian (arm 2) cancer. Overall response rate is defined as the proportion of patients who have a best overall response of complete response or partial response assessed per RECIST 1.1.
Outcome measures
| Measure |
BYL 200mg + AMG 12mg/kg
n=16 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 300mg + AMG 12mg/kg
n=6 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 350mg + AMG 12mg/kg
n=23 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
|---|---|---|---|
|
Percentage of Patients With Overall Response Rate (RECIST) Based on Investigator Radiology Assessment for HR Positive Breast and Ovarian Cancer - Phase II
|
12.5 Percentages of participants
Interval 1.6 to 38.3
|
16.7 Percentages of participants
Interval 0.4 to 64.1
|
13.0 Percentages of participants
Interval 2.8 to 33.6
|
SECONDARY outcome
Timeframe: Approximately 1 year (since FPFV 27Nov2012, till MTD declaration 26Nov2013)Population: Full Analysis set
The anti-tumor activity of alpelisib and ganitumab in combination as per RECIST 1.1
Outcome measures
| Measure |
BYL 200mg + AMG 12mg/kg
n=4 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 300mg + AMG 12mg/kg
n=10 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 350mg + AMG 12mg/kg
n=10 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
|---|---|---|---|
|
Number of Patients With Best Overall Response (RECIST) Based on Investigator Radiology Assessment - Phase Ib
Complete response (CR)
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Patients With Best Overall Response (RECIST) Based on Investigator Radiology Assessment - Phase Ib
Partial response (PR)
|
0 Participants
|
0 Participants
|
3 Participants
|
|
Number of Patients With Best Overall Response (RECIST) Based on Investigator Radiology Assessment - Phase Ib
Stable disease (PD)
|
1 Participants
|
3 Participants
|
2 Participants
|
|
Number of Patients With Best Overall Response (RECIST) Based on Investigator Radiology Assessment - Phase Ib
Progressive disease (PD)
|
3 Participants
|
3 Participants
|
3 Participants
|
|
Number of Patients With Best Overall Response (RECIST) Based on Investigator Radiology Assessment - Phase Ib
Unknown
|
0 Participants
|
4 Participants
|
2 Participants
|
SECONDARY outcome
Timeframe: Approximately 1 year (since FPFV 27Nov2012, till MTD declaration 26Nov2013)Population: Full Analysis set
The anti-tumor activity of alpelisib and ganitumab in combination as per RECIST 1.1
Outcome measures
| Measure |
BYL 200mg + AMG 12mg/kg
n=4 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 300mg + AMG 12mg/kg
n=33 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 350mg + AMG 12mg/kg
n=10 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
|---|---|---|---|
|
Percentage of Patients With Disease Control Rate (RECIST) Based on Investigator Radiology Assessment - Phase Ib
|
25.0 Percentages of participants
Interval 0.6 to 80.6
|
9.1 Percentages of participants
Interval 6.7 to 65.2
|
50.0 Percentages of participants
Interval 18.7 to 81.3
|
SECONDARY outcome
Timeframe: Approximately 1 year (since initiation of Phase II, Dec 2013, till Primary CSR cut off 06Jan2015)Population: Full analysis set
the antitumor activity of alpelisib in combination with ganitumab in patients with PIK3CA mutated or amplified hormone receptor positive (HR+) breast (arm 1) or ovarian (arm 2) cancer. Phase II only, Cycle 1 Day 1 through Cycle 6 Day 28; assessed at baseline and every 8 weeks thereafter
Outcome measures
| Measure |
BYL 200mg + AMG 12mg/kg
n=16 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 300mg + AMG 12mg/kg
n=6 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 350mg + AMG 12mg/kg
n=23 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
|---|---|---|---|
|
Percentage of Patients With Disease Control Rate (RECIST) Based on Investigator Radiology Assessment for HR Positive Breast and Ovarian Cancer - Phase II
|
43.8 Percentages of participants
Interval 19.8 to 70.1
|
50.0 Percentages of participants
Interval 11.8 to 88.2
|
47.8 Percentages of participants
Interval 26.8 to 69.4
|
SECONDARY outcome
Timeframe: Cycle 1 Day 1, Cycle 1 Day 15Population: Pharmacokinetic analysis set (PAS). The PAS included all patients who had at least one blood sample providing evaluable PK data. Patients were analyzed according to the dose level they actually received.
Serum concentration for BYL719 (alpelisib) 1 cycle - 28 days of treatment
Outcome measures
| Measure |
BYL 200mg + AMG 12mg/kg
n=4 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 300mg + AMG 12mg/kg
n=10 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 350mg + AMG 12mg/kg
n=10 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
|---|---|---|---|
|
Cmax of BYL - Phase Ib
Cycle 1 Day 1
|
2070 ng/mL
Standard Deviation 1040
|
2620 ng/mL
Standard Deviation 1260
|
2640 ng/mL
Standard Deviation 888
|
|
Cmax of BYL - Phase Ib
Cycle 1 day 15
|
3080 ng/mL
Standard Deviation 1750
|
2880 ng/mL
Standard Deviation 910
|
2600 ng/mL
Standard Deviation 1040
|
SECONDARY outcome
Timeframe: Cycle 1 Day 1 (0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose), Cycle 1 Day 15 (0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose)Population: Pharmacokinetic analysis set (PAS). The PAS included all patients who had at least one blood sample providing evaluable PK data. Patients were analyzed according to the dose level they actually received.
Area under curve for BYL719 (alpelisib) 1 cycle - 28 days of treatment
Outcome measures
| Measure |
BYL 200mg + AMG 12mg/kg
n=4 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 300mg + AMG 12mg/kg
n=10 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 350mg + AMG 12mg/kg
n=10 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
|---|---|---|---|
|
Area Under Curve (AUC) 0-24 Hour of BYL - Phase Ib
Cycle 1 Day 1
|
19900 hr*ng/mL
Standard Deviation 8700
|
23400 hr*ng/mL
Standard Deviation 10500
|
25200 hr*ng/mL
Standard Deviation 9200
|
|
Area Under Curve (AUC) 0-24 Hour of BYL - Phase Ib
Cycle 1 day 15
|
24000 hr*ng/mL
Standard Deviation 10700
|
29700 hr*ng/mL
Standard Deviation 9170
|
25200 hr*ng/mL
Standard Deviation 9160
|
SECONDARY outcome
Timeframe: Cycle 1 Day 1, Cycle 1 Day 15Population: Pharmacokinetic analysis set (PAS). The PAS included all patients who had at least one blood sample providing evaluable PK data. Patients were analyzed according to the dose level they actually received.
Tmax and half life of BYL719 (Alpelisib) 1 cycle - 28 days of treatment
Outcome measures
| Measure |
BYL 200mg + AMG 12mg/kg
n=4 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 300mg + AMG 12mg/kg
n=10 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 350mg + AMG 12mg/kg
n=10 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
|---|---|---|---|
|
Tmax and T Half of BYL - Phase Ib
Tmax (Cycle 1 Day 1)
|
2.78 hr
Interval 1.88 to 3.55
|
1.97 hr
Interval 0.63 to 3.0
|
2.36 hr
Interval 1.5 to 3.1
|
|
Tmax and T Half of BYL - Phase Ib
Tmax (Cycle 1 Day 15)
|
1.57 hr
Interval 0.83 to 1.83
|
3.01 hr
Interval 2.07 to 4.0
|
2.02 hr
Interval 2.0 to 3.08
|
|
Tmax and T Half of BYL - Phase Ib
Thalf (Cycle 1 Day 1)
|
7.78 hr
Interval 6.24 to 10.8
|
6.06 hr
Interval 5.26 to 13.7
|
6.86 hr
Interval 5.32 to 9.23
|
|
Tmax and T Half of BYL - Phase Ib
Thalf (Cycle 1 Day15)
|
6.89 hr
Interval 5.94 to 9.9
|
6.80 hr
Interval 5.82 to 8.81
|
6.83 hr
Interval 5.19 to 13.0
|
SECONDARY outcome
Timeframe: Cycle 1 Day 15Population: Pharmacokinetic analysis set (PAS). The PAS included all patients who had at least one blood sample providing evaluable PK data. Patients were analyzed according to the dose level they actually received.
Serum concentration for AMG 479 (ganitumab) 1 cycle - 28 days of treatment
Outcome measures
| Measure |
BYL 200mg + AMG 12mg/kg
n=4 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 300mg + AMG 12mg/kg
n=10 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 350mg + AMG 12mg/kg
n=10 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
|---|---|---|---|
|
Cmax of AMG - Phase Ib
|
192 ng/mL
Standard Deviation 24
|
202 ng/mL
Standard Deviation 43.3
|
232 ng/mL
Standard Deviation 59.3
|
SECONDARY outcome
Timeframe: Cycle 1 Day 15 (0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post-dose)Population: Pharmacokinetic analysis set (PAS). The PAS included all patients who had at least one blood sample providing evaluable PK data. Patients were analyzed according to the dose level they actually received.
Area under curve for AMG 479 (ganitumab) 1 cycle - 28 days of treatment
Outcome measures
| Measure |
BYL 200mg + AMG 12mg/kg
n=4 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 300mg + AMG 12mg/kg
n=10 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 350mg + AMG 12mg/kg
n=10 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
|---|---|---|---|
|
Area Under Curve (AUC) 0-336 Hour of AMG - Phase Ib
|
22900 hr*ng/mL
Standard Deviation 3930
|
22500 hr*ng/mL
Standard Deviation 7040
|
25200 hr*ng/mL
Standard Deviation 8000
|
SECONDARY outcome
Timeframe: Cycle 1 Day 15Population: Pharmacokinetic analysis set (PAS). The PAS included all patients who had at least one blood sample providing evaluable PK data. Patients were analyzed according to the dose level they actually received.
Tmax and half life of AMG 479 (ganitumab) 1 cycle - 28 days of treatment
Outcome measures
| Measure |
BYL 200mg + AMG 12mg/kg
n=4 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 300mg + AMG 12mg/kg
n=10 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 350mg + AMG 12mg/kg
n=10 Participants
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
|---|---|---|---|
|
Tmax and T Half of AMG - Phase Ib
Tmax
|
21.20 hr
Interval 1.02 to 22.7
|
1.02 hr
Interval 1.0 to 23.1
|
1.07 hr
Interval 1.0 to 1.77
|
|
Tmax and T Half of AMG - Phase Ib
Thalf
|
132 hr
Interval 117.0 to 148.0
|
117 hr
Interval 109.0 to 161.0
|
180 hr
Interval 98.0 to 283.0
|
Adverse Events
BYL 200mg + AMG 12 mg/kg
Serious events: 1 serious events
Other events: 4 other events
Deaths: 4 deaths
BYL 300mg + AMG 12 mg/kg
Serious events: 5 serious events
Other events: 10 other events
Deaths: 8 deaths
BYL 350mg + AMG 12 mg/kg
Serious events: 5 serious events
Other events: 10 other events
Deaths: 8 deaths
HR + BC - Phase II
Serious events: 9 serious events
Other events: 16 other events
Deaths: 13 deaths
Ovarian - Phase II
Serious events: 5 serious events
Other events: 6 other events
Deaths: 5 deaths
Serious adverse events
| Measure |
BYL 200mg + AMG 12 mg/kg
n=4 participants at risk
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 300mg + AMG 12 mg/kg
n=10 participants at risk
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 350mg + AMG 12 mg/kg
n=10 participants at risk
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
HR + BC - Phase II
n=16 participants at risk
Patients with PIK3CA mutated or amplified hormone receptor (HR) positive breat carcinoma (BC) were treated with alpelisib 300 mg once daily and ganitumab 12 mg/kg
|
Ovarian - Phase II
n=6 participants at risk
Patients with other than Breast and Ovarian cancer treated in the phase II
|
|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Large intestinal obstruction
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Asthenia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Fatigue
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Pyrexia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Hepatobiliary disorders
Bile duct stenosis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Hepatobiliary disorders
Bile duct stone
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Immune system disorders
Drug hypersensitivity
|
25.0%
1/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Abdominal abscess
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Escherichia sepsis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Lung infection
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Subcutaneous abscess
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Injury, poisoning and procedural complications
Fracture displacement
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Investigations
Blood creatinine increased
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
50.0%
3/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Musculoskeletal and connective tissue disorders
Myositis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Nervous system disorders
Convulsion
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Nervous system disorders
Generalised tonic-clonic seizure
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Renal and urinary disorders
Renal failure acute
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Reproductive system and breast disorders
Female genital tract fistula
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Acute interstitial pneumonitis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Pleuritic pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
Other adverse events
| Measure |
BYL 200mg + AMG 12 mg/kg
n=4 participants at risk
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 300mg + AMG 12 mg/kg
n=10 participants at risk
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
BYL 350mg + AMG 12 mg/kg
n=10 participants at risk
BYL719 (alpelisib) and AMG 479 (ganitumab) regimen in patients with PIK3CA mutated or amplified solid tumors
|
HR + BC - Phase II
n=16 participants at risk
Patients with PIK3CA mutated or amplified hormone receptor (HR) positive breat carcinoma (BC) were treated with alpelisib 300 mg once daily and ganitumab 12 mg/kg
|
Ovarian - Phase II
n=6 participants at risk
Patients with other than Breast and Ovarian cancer treated in the phase II
|
|---|---|---|---|---|---|
|
Gastrointestinal disorders
Dry mouth
|
25.0%
1/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
30.0%
3/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
18.8%
3/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Dyspepsia
|
25.0%
1/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
50.0%
3/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Nervous system disorders
Headache
|
75.0%
3/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
31.2%
5/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Nervous system disorders
Memory impairment
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
50.0%
3/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Blood and lymphatic system disorders
Leukocytosis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Nervous system disorders
Paraesthesia
|
25.0%
1/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Blood and lymphatic system disorders
Lymph node pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Cardiac disorders
Bradycardia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Cardiac disorders
Palpitations
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
33.3%
2/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Ear and labyrinth disorders
Ear congestion
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Ear and labyrinth disorders
Ear pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Ear and labyrinth disorders
Hearing impaired
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Ear and labyrinth disorders
Tinnitus
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Eye disorders
Eye swelling
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Eye disorders
Eyelid ptosis
|
25.0%
1/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Eye disorders
Periorbital oedema
|
25.0%
1/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Eye disorders
Photopsia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Eye disorders
Vision blurred
|
25.0%
1/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
18.8%
3/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
33.3%
2/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Abdominal pain lower
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
25.0%
1/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Anal fissure
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Anal ulcer
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Anorectal discomfort
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Aphthous stomatitis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Chapped lips
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
30.0%
3/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
25.0%
4/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Diarrhoea
|
50.0%
2/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
50.0%
5/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
70.0%
7/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
62.5%
10/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
50.0%
3/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Flatulence
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Gingival bleeding
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Gingival erosion
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Gingival recession
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Mouth ulceration
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
90.0%
9/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
50.0%
5/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
43.8%
7/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
50.0%
3/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Odynophagia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Oesophagitis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Oral pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Retching
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Sensitivity of teeth
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Stomatitis
|
75.0%
3/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
30.0%
3/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
50.0%
5/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
37.5%
6/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
50.0%
3/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Toothache
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
60.0%
6/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
40.0%
4/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
25.0%
4/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
50.0%
3/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Asthenia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
18.8%
3/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
50.0%
3/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Axillary pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Catheter site pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Chills
|
25.0%
1/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
18.8%
3/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Face oedema
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Fatigue
|
50.0%
2/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
60.0%
6/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
80.0%
8/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
43.8%
7/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
33.3%
2/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Feeling abnormal
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Feeling cold
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Gait disturbance
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Injection site rash
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Instillation site pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Localised oedema
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Malaise
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Mucosal inflammation
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
18.8%
3/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
18.8%
3/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Oedema peripheral
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Pyrexia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
25.0%
4/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
General disorders
Thirst
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Hepatobiliary disorders
Cholangitis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Immune system disorders
Drug hypersensitivity
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Immune system disorders
Seasonal allergy
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Abscess limb
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Conjunctivitis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Gastroenteritis viral
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Gingivitis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Herpes virus infection
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Localised infection
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Nail infection
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Nasal herpes
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Onychomycosis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Oral candidiasis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Paronychia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Periorbital cellulitis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Pharyngitis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Rash pustular
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Subcutaneous abscess
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
18.8%
3/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Infections and infestations
Vulvovaginal mycotic infection
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Injury, poisoning and procedural complications
Hip fracture
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
25.0%
1/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Injury, poisoning and procedural complications
Wound
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Injury, poisoning and procedural complications
Wound complication
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Investigations
Activated partial thromboplastin time prolonged
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Investigations
Amylase increased
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
25.0%
4/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
33.3%
2/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
33.3%
2/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Investigations
Blood calcium decreased
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Investigations
Blood cholesterol increased
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Investigations
Blood creatine phosphokinase MB increased
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Investigations
Blood creatine phosphokinase increased
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Investigations
Blood creatinine increased
|
75.0%
3/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
30.0%
3/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
33.3%
2/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Investigations
Blood magnesium decreased
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Investigations
Blood phosphorus decreased
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Investigations
Electrocardiogram QT prolonged
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Investigations
Lipase increased
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Investigations
Neutrophil count decreased
|
25.0%
1/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Investigations
Neutrophil count increased
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Investigations
Platelet count decreased
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Investigations
Weight decreased
|
50.0%
2/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
50.0%
5/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
90.0%
9/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
37.5%
6/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
33.3%
2/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
25.0%
1/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
50.0%
5/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
60.0%
6/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
50.0%
8/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
100.0%
6/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Metabolism and nutrition disorders
Dehydration
|
25.0%
1/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
50.0%
5/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
40.0%
4/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
25.0%
4/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Metabolism and nutrition disorders
Glucose tolerance impaired
|
25.0%
1/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Metabolism and nutrition disorders
Gout
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
25.0%
1/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
70.0%
7/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
90.0%
9/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
56.2%
9/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
66.7%
4/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
30.0%
3/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Metabolism and nutrition disorders
Metabolic acidosis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
25.0%
1/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
25.0%
4/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
18.8%
3/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
25.0%
1/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
25.0%
4/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
18.8%
3/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal discomfort
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
18.8%
3/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Musculoskeletal and connective tissue disorders
Myositis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
31.2%
5/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Musculoskeletal and connective tissue disorders
Spinal pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Musculoskeletal and connective tissue disorders
Trismus
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Nervous system disorders
Amnesia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Nervous system disorders
Aphonia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Nervous system disorders
Balance disorder
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Nervous system disorders
Disturbance in attention
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Nervous system disorders
Dizziness
|
25.0%
1/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
30.0%
3/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
30.0%
3/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
33.3%
2/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Nervous system disorders
Dysarthria
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Nervous system disorders
Dysgeusia
|
25.0%
1/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
40.0%
4/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
40.0%
4/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
18.8%
3/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Nervous system disorders
Presyncope
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
33.3%
2/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Nervous system disorders
Somnolence
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
33.3%
2/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Nervous system disorders
Transient ischaemic attack
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Psychiatric disorders
Agitation
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Psychiatric disorders
Depression
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
40.0%
4/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Psychiatric disorders
Libido decreased
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Psychiatric disorders
Mental status changes
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Renal and urinary disorders
Bladder spasm
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Renal and urinary disorders
Cystitis noninfective
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Renal and urinary disorders
Dysuria
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Renal and urinary disorders
Hydronephrosis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Renal and urinary disorders
Micturition urgency
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Renal and urinary disorders
Neurogenic bladder
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Renal and urinary disorders
Pollakiuria
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Renal and urinary disorders
Polyuria
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Renal and urinary disorders
Renal failure acute
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Renal and urinary disorders
Renal impairment
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Renal and urinary disorders
Urinary tract pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Reproductive system and breast disorders
Breast pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Reproductive system and breast disorders
Pelvic pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Reproductive system and breast disorders
Vulvovaginal dryness
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Atelectasis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Choking
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
37.5%
6/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
33.3%
2/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
40.0%
4/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
25.0%
4/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Laryngeal haemorrhage
|
25.0%
1/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Paranasal sinus discomfort
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Paranasal sinus hypersecretion
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory tract congestion
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinitis allergic
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
18.8%
3/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Sinus congestion
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Respiratory, thoracic and mediastinal disorders
Upper-airway cough syndrome
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Acanthosis nigricans
|
25.0%
1/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Blister
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Dermatitis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Dermatitis acneiform
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Ingrowing nail
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Nail disorder
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Night sweats
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Onychoclasis
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Prurigo
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
25.0%
4/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
16.7%
1/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
25.0%
4/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Rash erythematous
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Rash macular
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
50.0%
2/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
20.0%
2/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
31.2%
5/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Rash pruritic
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Skin discolouration
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Vascular disorders
Flushing
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Vascular disorders
Hypertension
|
50.0%
2/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Vascular disorders
Hypotension
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
6.2%
1/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Vascular disorders
Lymphoedema
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
12.5%
2/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
|
Vascular disorders
Peripheral venous disease
|
0.00%
0/4 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
10.0%
1/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/10 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/16 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
0.00%
0/6 • Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 4.5 years.
One patients with a tumor type other than Breast and Ovarian treated in the phase II part not represented.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.
- Publication restrictions are in place
Restriction type: OTHER